← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-11 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleYonsei UniversityPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleEli LillyApproved

Treatment of Encorafenib & Binimetinib & Cetuximab (Treatment of Encorafenib & Binimetinib & Cetuximab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRabin Medical CenterPreclinical

adalimumab (Humira, Treatment with Adalimumab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE
AntibodystaleJanssenApproved

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab (Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleChia Tai Tianqing Pharmaceutica…Phase 3

Trifluridine /Tipiracil (TAS-102, Trifluridine /Tipiracil, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets)

HER2 IHC3+ Advanced Colorectal Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

TAS-102 (Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102))

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Dynamic Tumor Resistance

#DynamicTumorResistance#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine/tipiracil (TAS-102, Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102) plus bevacizumab)

Colo-rectal Cancer; Third-line and Beyond Therapy · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Unicar-Therapy Bio-med…Phase 1

Triple-targeted CAR-T Therapy (Triple-targeted CAR-T Therapy)

B-cell Lymphoma · B-cell Lymphoma

#B-cellLymphoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

etanercept, infliximab, adalimumab, and golimumab (Tumor Necrosis Factor Inhibitor, Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab))

Infection; Rheumatoid Arthritis · Infection

#Infection#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

Tunlametinib + Cetuximab β (Tunlametinib + Cetuximab β)

Lung Cancer (NSCLC) · Lung Cancer (NSCLC)

#LungCancerNSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

159 / 177 페이지

← 이전다음 →